Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Enspryng 120 mg solution for injection in pre-filled syringe

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Satralizumab may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Satralizumab
Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for

What Enspryng is Enspryng contains the active substance satralizumab. It is a type of protein called a monoclonal antibody. Monoclonal antibodies are designed to recognise and attach to a specific substance in the body. What Enspryng is used for Enspryng is a medicine for treating neuromyelitis optica spectrum disorders (NMOSD) in adults and young people from 12 years of age. What is NMOSD NMOSD is a disease of the central nervous system that mainly affects the optic nerves and spinal cord. It is caused by the immune system (the body's defences) working incorrectly and attacking nerves in the body.

  • The damage to the optic nerves causes swelling, leading to pain and loss of sight.
  • The damage to the spinal cord causes weakness or loss of movement in the legs or arms, loss of feeling, and problems with bladder and bowel function. In an attack of NMOSD, there is swelling in the nervous system. This also happens when the disease comes back (relapse). The swelling causes new symptoms or a return of previous symptoms.

1 uk-pil-enspryng-clean-260429-120mg-pfs

How Enspryng works Enspryng blocks the action of a protein called interleukin-6 (IL-6), which is involved in the processes that lead to damage and swelling in the nervous system. By blocking its effects, Enspryng reduces the risk of a relapse or attack of NMOSD. 2.

What you need to know before you take it

e Enspryng

Do not use Enspryng

  • if you are allergic to satralizumab or any of the other ingredients of this medicine (listed in section 6). If the above applies to you or you are not sure, do not use Enspryng and talk to your doctor, pharmacist or nurse. Warnings and precautions Talk to your doctor immediately if you experience any allergic reaction (see section 4. Possible side effects). Talk to your doctor, pharmacist or nurse before using Enspryng if any of the below apply to you (or if you are not sure). Infections You cannot use Enspryng while you have an infection. Tell your doctor or nurse straight away if you think you have any signs of infection before, during, or after Enspryng treatment such as:
  • fever or chills
  • cough that does not go away
  • sore throat
  • cold sore or genital sores (herpes simplex)
  • shingles (herpes zoster)
  • skin redness, swelling, tenderness or pain
  • feeling or being sick, diarrhoea or belly pain. You will also find this information in the patient alert card you have been given by your doctor. It is important that you keep this alert card with you at all times and show it to any doctor, nurse or caregiver. Your doctor will wait until the infection is controlled before giving you Enspryng or allowing you to continue to inject Enspryng. Vaccinations Tell your doctor if you have recently been given any vaccine or might be given a vaccine in the near future.
  • Your doctor will check if you need any vaccines before you start Enspryng.
  • Do not have live or live attenuated vaccines (for example BCG for tuberculosis or vaccines against yellow fever) while you are being treated with Enspryng. Liver enzymes Enspryng can have effects on your liver and increase the amount of some liver enzymes in your blood. Your doctor will do blood tests before you are given Enspryng, and during your treatment, to check how well your liver is working. Tell your doctor or nurse straight away if you have any of these signs of liver damage during or after Enspryng treatment: • yellowing of the skin and the whites of the eyes (jaundice) • dark-coloured urine • feeling and being sick 2 uk-pil-enspryng-clean-260429-120mg-pfs

•

abdominal pain

White blood cell count Your doctor will perform blood tests before you are given Enspryng, and during your treatment, to check your white blood cell count. Children and young people Do not give this medicine to children under 12 years of age. This is because it has not yet been studied in this age group. Other medicines and Enspryng Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Tell your doctor or pharmacist if you are taking medicines such as warfarin, carbamazepine, phenytoin and theophylline as doses might need to be adjusted. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Your doctor may advise you to stop breast-feeding if you are to be given Enspryng. It is not known whether Enspryng passes into breast milk. Driving and using machines Enspryng is not likely to affect you being able to drive, cycle or use any tools or machines. 3.

How to use Enspryng

Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. How much Enspryng to use Each injection contains 120 mg of satralizumab. The first injection will be given under the supervision of your doctor or nurse.

  • The first three injections are given once every 2 weeks. These are called 'loading doses'.
  • After this, the injection is given every 4 weeks. This is called the 'maintenance dose'. Continue with the injections once every 4 weeks for as long as your doctor tells you to.

How to take it

Enspryng

  • Enspryng is given by injection under the skin (sub-cutaneously).
  • Inject the entire content of the syringe each time. At the start, your doctor or nurse may inject Enspryng. However, your doctor may decide that you or an adult caregiver can inject Enspryng.
  • You or your caregiver will get training on how to inject Enspryng.
  • Talk to your doctor or nurse if you or your caregiver have any questions about giving injections. Read carefully and follow the "Instructions for use" at the end of this leaflet on how to inject Enspryng. If you use more Enspryng than you should Because Enspryng is in a pre-filled syringe, it is unlikely that you will receive too much. However, if you are worried, talk to your doctor, pharmacist or nurse.

3 uk-pil-enspryng-clean-260429-120mg-pfs

If you accidentally inject more doses than you should, call your doctor. Always take the outer carton with you when you go to see the doctor. If you forget to use Enspryng For the treatment to be fully effective, it is very important to keep having the injections. If your doctor or nurse is giving your injections and you miss an appointment, make another one straight away. If you are injecting Enspryng yourself and you miss an injection, inject it as soon as possible. Do not wait until the next planned dose. After you have had the injection for the missed dose, your next injection should be either:

  • for loading doses – 2 weeks later
  • for maintenance doses – 4 weeks later Check with your doctor, pharmacist or nurse if you are not sure. If you stop using Enspryng Do not suddenly stop using Enspryng without asking your doctor first. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. 4.

Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. Allergic reactions Tell your doctor straight away or go to the emergency department of your nearest hospital, if you have any signs of allergic reactions during or after the injection. They include:

  • tight chest or wheezing
  • feeling short of breath
  • fever or chills
  • severe dizziness or light-headedness
  • swelling of the lips, tongue, face
  • skin itching, hives or rash. Do not take the next dose until you have spoken with your doctor and your doctor has told you to take the next dose. Injection-related reactions (very common: may affect more than 1 in 10 people) In most cases these are mild reactions, but some can be serious. Tell your doctor or nurse straight away if you have any of these signs during or after the injection, particularly in the first 24 hours after the injection:
  • redness, itching, pain or swelling where the injection is given
  • rash, red or itchy skin or hives
  • feeling flushed
  • headache
  • throat irritation, swelling or pain
  • feeling short of breath
  • low blood pressure (dizziness and light-headedness)
  • fever or chills
  • feeling tired
  • feeling or being sick, or diarrhoea
  • fast heart rate, fluttering or pounding heart (palpitations). Tell your doctor or nurse straight away if you have any of the signs above. 4 uk-pil-enspryng-clean-260429-120mg-pfs

Other side effects: Very common (may affect more than 1 in 10 people)

  • headache
  • joint pain
  • high levels of blood lipids (fats)
  • low level of white blood cells in tests Common (may affect up to 1 in 10 people)
  • feeling stiff
  • migraine
  • slow heart beat (bradycardia)
  • increase in blood pressure
  • being unable to sleep
  • swelling in your lower legs, feet or hands
  • rash or itching
  • allergies or hay fever
  • stomach inflammation (gastritis), including stomach pain and nausea
  • weight increase
  • blood tests showing: − low fibrinogen levels (a protein involved in blood clotting) − high level of liver enzymes (transaminases, possible sign of liver problems) − high level of bilirubin (possible sign of liver problems) − low level of platelets (which may lead to bleeding or bruising easily) Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine. 5.

How to store it

Enspryng

  • Keep this medicine out of the sight and reach of children.
  • Do not use this medicine after the expiry date which is stated on the pre-filled syringe label and carton after 'EXP'. The expiry date refers to the last day of that month.
  • Store in a refrigerator (2°C – 8°C). Do not freeze. Do not use the syringe if it has been frozen. Always keep the syringe dry.
  • Keep the pre-filled syringes in the outer carton in order to protect from light and moisture.
  • If unopened and kept in the outer carton, Enspryng may be left out of the refrigerator below 30°C for a single period up to 8 days. Do not return Enspryng to the refrigerator.
  • Do not use and discard the pre-filled syringe if it has been left out of the refrigerator for longer than 8 days. Do not use this medicine if it is cloudy, discoloured or contains particles. Enspryng is a colourless to slightly yellow liquid. The medicine must be injected right after removing the cap and no later than 5 minutes to prevent the medicine from drying out and blocking the needle. If the pre-filled syringe is not used within 5 minutes of removing the cap, you must dispose of it in a puncture-resistant container and use a new pre-filled syringe.

5 uk-pil-enspryng-clean-260429-120mg-pfs

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6.

Contents of the pack and other information

What Enspryng contains

  • The active substance is satralizumab. Each pre-filled syringe contains 120 mg of satralizumab in 1 mL.
  • The other ingredients are histidine, aspartic acid, arginine, poloxamer 188, water for injections. What Enspryng looks like and contents of the pack
  • It is a colourless to slightly yellow liquid.
  • Enspryng is a solution for injection.
  • Enspryng is available in packs containing 1 pre-filled syringe and in multipacks comprising 3 cartons, each carton contains 1 pre-filled syringe. Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer Roche Products Limited 6 Falcon Way, Shire Park Welwyn Garden City AL7 1TW, United Kingdom This leaflet was last revised in February 2026.

6 uk-pil-enspryng-clean-260429-120mg-pfs

Instructions for use Read these instructions for use:

  • Before you start using your pre-filled syringe
  • Each time you get a prescription refill, because it may contain new information.
  • This information does not take the place of talking to your doctor or nurse about your medical condition or treatment.
  • Your doctor or nurse will decide if you or a caregiver can give you injections of Enspryng at home. They will also show you or a caregiver the correct and safe way to use the syringe before you use it for the first time.
  • Talk to your doctor or nurse if you have any questions. Important Information
  • Each syringe is pre-filled with a medicine called Enspryng.
  • Each carton of Enspryng contains only 1 pre-filled syringe.
  • Each pre-filled syringe can be used only once.
  • Do not share your syringes with other people.
  • Do not take the needle cap off until you are ready to inject Enspryng.
  • Do not use the syringe if it has been dropped or damaged.
  • Do not try to take the syringe apart at any time.
  • Do not leave the syringe unattended.
  • Do not re-use the same syringe.

Supplies needed to give your injection Each Enspryng carton contains:

  • 1 pre-filled syringe for one-time use only. You also need the following but they are not included in the carton:

• • • •

1 alcohol pad 1 sterile cotton ball or gauze 1 small bandage 1 puncture-resistant sharps container for safe disposal of the needle cap and used syringe. See step 21 "Disposing of Enspryng" at the end of these instructions for use.

7 uk-pil-enspryng-clean-260429-120mg-pfs

Enspryng pre-filled syringe (See Figure A and Figure B) Before use: Activation guards (Do not touch)

Barrel

Needle cap

Expiry date

Plunger

Figure A After use:

Automatic needle-guard (extended and locked)

Figure B The syringe has an automatic needle-guard that covers the needle when the injection is complete.

Prepare to use Enspryng 1. Take the carton containing the syringe out of the refrigerator and place it on a clean, flat work surface (like a table). 2. Check the expiry date on the back of the carton (see Figure C). Do not use if the carton has expired. 3. Check that the front of the carton is sealed (see Figure C). Do not use if the seal is broken. If the expiry date has passed or the seal is broken, go to step 21 "Disposing of Enspryng" and contact your doctor or nurse.

Figure C

8 uk-pil-enspryng-clean-260429-120mg-pfs

4. Open the sealed carton (see Figure D).

Figure D 5. Carefully lift the syringe out of the carton by holding the barrel (see Figure E).

  • Do not turn the carton upside down to remove the syringe.
  • Do not touch the activation guards. This may damage the syringe.
  • Do not hold the plunger or needle cap.

Figure E Check the syringe (See Figure F) 6. Check the expiry date on the syringe. Do not use the syringe if it has expired. 7. Check the syringe for any damage. Do not use if it is cracked or broken. 8. Check that the liquid through the viewing window is clear and colourless to slightly yellow. Do not inject the medicine if the liquid is cloudy, discoloured, or has particles in it.

  • There may be some small air bubbles in the syringe. This is normal and you should not try to remove them.
  • Check expiry date
  • Check liquid
  • Check syringe for damage

Figure F If the expiry date has passed, the syringe is damaged or the liquid is cloudy, discoloured or has particles in it, do not use. Then go to step 21 "Disposing of Enspryng" and contact your doctor or nurse.

9 uk-pil-enspryng-clean-260429-120mg-pfs

Let your syringe get to room temperature 9. Once you have checked the syringe, place it on a clean, flat work surface (like a table) for 30 minutes. This will allow it to reach room temperature (see Figure G). It is important to let the syringe gently reach room temperature because injecting cold medicine may feel uncomfortable and make it harder to push the plunger.

  • Do not speed up the warming process by heating the syringe in any way.
  • Do not remove the needle cover while the syringe is reaching room temperature.

Figure G Wash your hands 10. Wash your hands with soap and water (see Figure H).

Figure H Choose the injection site 11. Choose your injection site in either:

  • the lower part of your stomach (abdomen) or,
  • the front and middle of your thighs (see Figure I).

Injection site areas

Figure I

  • Do not inject into the 5 cm area around your belly button.
  • Do not inject into moles, scars, bruises, or areas where the skin is tender, red, hard or broken. Choose a different injection site for each new injection. Choose a different site for each new injection at least 2.5 cm away from the place used last time. Clean the injection site 12. Wipe the injection site with an alcohol pad and let it air dry.

10 uk-pil-enspryng-clean-260429-120mg-pfs

• •

Do not fan or blow on the area which you have cleaned. Do not touch the injection site again before you give the injection.

Figure J Inject Enspryng 13. Hold the barrel of the syringe between your thumb and index finger. With your other hand, pull the needle cap straight off. You may see a drop of liquid at the end of the needle. This is normal and will not affect your dose (see Figure K).

  • Use the syringe within 5 minutes of removing the cap or the needle may clog.
  • Do not take the needle cap off until you are ready to inject Enspryng.
  • Do not put the needle cap back on once it has been removed as this may damage the needle.
  • Do not touch the needle or let it touch any surfaces after removing the needle cap.

Figure K 14. Throw away the needle cap in a puncture-resistant sharps container immediately. See step 21 "Disposing of Enspryng". 15. Hold the barrel of the syringe using your thumb and index finger. With your other hand, pinch the area of skin you have cleaned (see Figure L). 16. Use a quick, dart-like motion to insert the needle at an angle between 45° to 90° (see Figure L).

  • Do not change the angle of the injection while performing the injection.
  • Do not insert the needle again.

Figure L 17. After the needle is inserted, let go of the pinched skin.

11 uk-pil-enspryng-clean-260429-120mg-pfs

18. Slowly inject all of the medicine by gently pushing the plunger all the way down until it touches the activation guards (see Figure M).

Figure M 19. Gently release the plunger and allow the needle to come out of the skin at the same angle it was inserted (see Figure N).

•

Figure N The needle will now be covered by the automatic needle-guard. If the needle is not covered, carefully place the syringe into a puncture-resistant sharps container to avoid injury. See step 21 "Disposing of Enspryng".

Taking care of the injection site 20. There may be a little bleeding at the injection site. You can press a cotton ball or gauze over the injection site until any bleeding stops but do not rub it. If needed, you may also cover the area you injected with a small bandage. If the medicine comes into contact with your skin, wash the area with water. Disposing of Enspryng 21. Do not try to re-cap your syringe. Put your used syringe in a sharps disposal container immediately after use (see Figure O). Do not throw the syringe in your household waste and do not recycle it.

• • • •

Figure O Ask your doctor or nurse or pharmacist for information about where you can get a "sharps" container or what other types of puncture-resistant containers you can use to safely dispose of your used syringes and needle caps. Dispose of the used sharps disposal container as instructed by your healthcare provider or pharmacist. Do not dispose of your used sharps disposal container in your household waste. Do not recycle your used sharps disposal container. 12 uk-pil-enspryng-clean-260429-120mg-pfs

Frequently asked questions about Enspryng 120 mg solution for injection in pre-filled syringe

How do I take Enspryng 120 mg solution for injection in pre-filled syringe?

Enspryng 120 mg solution for injection in pre-filled syringe comes as injection containing 120mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Enspryng 120 mg solution for injection in pre-filled syringe?

The active substance in Enspryng 120 mg solution for injection in pre-filled syringe is satralizumab.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Enspryng 120 mg solution for injection in pre-filled syringe, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Enspryng 120 mg solution for injection in pre-filled syringe without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Satralizumab (1 medicine)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Enspryng is indicated as a monotherapy or in combination with immunosuppressive therapy (IST) for the treatment of neuromyelitis optica spectrum disorders (NMOSD) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 IgG (AQP4-IgG) seropositive (see section 5.1).

4.2. Posology and method of administration

Treatment should be initiated under the supervision of a physician experienced in the treatment of neuromyelitis optica (NMO) or NMOSD.

Posology

Enspryng can be used as a monotherapy or in combination with oral corticosteroids (OCs), azathioprine (AZA) or mycophenolate mofetil (MMF) (see section 5.1). The posology in adolescent patients ≥12 years of age with body weight ≥ 40 kg and adult patients is the same.

Loading doses

The recommended loading dose is 120 mg subcutaneous injection every two weeks for the first three administrations (first dose at week 0, second dose at week 2 and third dose at week 4).

Maintenance doses

The recommended maintenance dose is 120 mg subcutaneous injection every four weeks.

Duration of treatment

Enspryng is intended for long-term treatment.

Delayed or missed doses

If an injection is missed, for any reason other than increases in liver enzymes, it should be administered as described in table 1.

Table 1: Recommended dose for delayed or missed doses

Last dose administered

Recommended dose for delayed or missed doses

Missed a loading dose or less than 8 weeks during the maintenance period

The recommended dose should be administered as soon as possible without waiting until the next planned dose.

Loading period

If the second loading dose is delayed or missed, this dose should be administered as soon as possible and the third and final loading dose 2 weeks later.

If the third loading dose is delayed or missed, this dose should be administered as soon as possible and the first maintenance dose 4 weeks later.

Maintenance period

After the delayed or missed dose is administered, the dosing schedule should be reset to every 4 weeks.

8 weeks to less than 12 weeks

The recommended dose should be administered at 0*, 2 weeks and every 4 weeks thereafter.

12 weeks or longer

The recommended dose should be administered at 0*, 2, 4 weeks and every 4 weeks thereafter.

* “0 weeks” refers to time of the first administration after the missed dose.

Dose modification advice for liver enzyme abnormalities

If the alanine aminotransferase (ALT) or aspartate transaminase (AST) elevation is >5 x upper limit of normal (ULN) and associated with any bilirubin elevation, treatment must be discontinued, and reinitiation is not recommended.

If the ALT or AST elevation is >5 x ULN and not associated with any bilirubin elevation, treatment should be discontinued. Treatment can be restarted at a dose of 120 mg subcutaneous injection every four weeks when the ALT and AST levels have returned to the normal range and based on assessment of benefit-risk of treatment in the patient. If the decision is taken to restart treatment, liver parameters must be closely monitored, and if any subsequent increase in ALT/AST and/or bilirubin is observed, treatment must be discontinued, and reinitiation is not recommended (see sections 4.4 and 4.8).

Table 2: Recommended dose for restart of treatment after liver transaminase elevation

Last dose administered

Recommended dose for restart of treatment

Less than 12 weeks

Treatment should be restarted using the recommended dose, given every 4 weeks.

12 weeks or longer

Treatment should be restarted using the recommended dose, given at weeks 0*, 2, 4 and every 4 weeks thereafter.

* “0 weeks” refers to time of the first administration after the restart of treatment.

Dose modification advice for neutropenia

If the neutrophil count is below 1.0 x 109/L and confirmed by repeat testing, treatment should be interrupted until the neutrophil count is >1.0 x 109/L.

Dose modification advice for low platelet count

If the platelet count is below 75 x 109/L and confirmed by repeat testing, treatment should be interrupted until the platelet count is ≥75 x 109/L.

Special populations

Paediatric population

The posology in adolescent patients ≥12 years of age with body weight ≥ 40 kg and adult patients is the same (see sections 5.1 and 5.2). The safety and efficacy of satralizumab in children with body weight < 40 kg have not yet been established. No data are available.

Elderly

No dose adjustment is required in patients ≥65 years of age (see section 5.2).

Renal impairment

The safety and efficacy of satralizumab have not been formally studied in patients with renal impairment. No dose adjustment is recommended for patients with mild renal impairment (see section 5.2).

Hepatic impairment

The safety and efficacy of satralizumab have not been studied in patients with hepatic impairment. No data are available (see section 5.2).

Elevations of liver enzymes have been observed during treatment with satralizumab (see sections 4.4 and 4.8). For dose adjustment, see above section Dose modification advice for liver enzyme abnormalities.

Method of administration

Satralizumab 120 mg is administered by subcutaneous injection using a single-dose pre-filled syringe. The total content (1 mL) of the pre-filled syringe should be administered.

The recommended injection sites are the abdomen and thigh. Injection sites should be rotated and injections should never be given into moles, scars, or areas where the skin is tender, bruised, red, hard, or not intact.

Comprehensive instructions for the administration of satralizumab are given at the end of the package leaflet.

Administration by the patient and/or caregiver

The first injection must be performed under the supervision of a qualified Healthcare Professional (HCP).

After adequate training on how to prepare and perform the injection, an adult patient/caregiver may administer all other doses at home if the treating physician determines that it is appropriate and the adult patient/caregiver can perform the injection technique.

Patients/caregivers should seek immediate medical attention if the patient develops symptoms of serious allergic reactions and should check with their HCP to confirm whether treatment can be continued or not.

4.3. Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4. Special warnings and precautions for use

Traceability

In order to improve traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Infections

Administration of satralizumab should be delayed in patients with an active infection until the infection is controlled (see section 4.2).

Vigilance for the timely detection and diagnosis of infection is recommended for patients receiving treatment with satralizumab. Treatment should be delayed in case the patient develops any serious or opportunistic infection and appropriate therapy should be initiated under further monitoring. Patients should be instructed on seeking early medical attention in case of signs and symptoms of infections to facilitate timely diagnosis of infections. Patients should be provided with a patient alert card.

Vaccinations

Live and live-attenuated vaccines should not be given concurrently with satralizumab as clinical safety has not been established. The interval between live vaccinations and initiation of satralizumab treatment should be in accordance with current vaccination guidelines regarding immunomodulatory or immunosuppressive agents.

No data are available on the effects of vaccination in patients receiving satralizumab. It is recommended that all patients be brought up to date with all immunisations in agreement with current immunisation guidelines prior to initiating satralizumab treatment.

Liver enzymes

Mild and moderate elevations of liver transaminases have been observed with satralizumab treatment, most elevations were below 5 x ULN (see section 4.8).

ALT and AST levels should be monitored every four weeks for the first three months of treatment, followed by every three months for one year, thereafter as clinically indicated.

Treatment with satralizumab should be discontinued in patients with ALT or AST >5 x ULN (see section 4.2).

Neutrophil count

Decreases in neutrophil counts have occurred following treatment with satralizumab (see section 4.8). Neutrophil counts should be monitored 4 to 8 weeks after start of treatment and thereafter as clinically indicated. For recommended dose interruption see section 4.2.

4.5. Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed.

Population pharmacokinetic (PK) analyses did not detect any effect of azathioprine (AZA), oral corticosteroids (OCs) or mycophenolate mofetil (MMF) on the clearance of satralizumab.

Both in vitro and in vivo studies have shown that the expression of specific hepatic CYP450 enzymes (CYP1A2, CYP2C9, CYP2C19, and CYP3A4) is suppressed by cytokines such as IL-6.

Therefore caution should be exercised when starting or discontinuing satralizumab treatment in patients also receiving substrates of CYP450 3A4, 1A2, 2C9 or 2C19, particularly those with a narrow therapeutic index (such as warfarin, carbamazepine, phenytoin and theophylline), and doses adjusted if needed.

Given the prolonged terminal half-life of satralizumab, the effect of satralizumab may persist for several weeks after stopping treatment.

4.6. Fertility, pregnancy and lactation

Pregnancy

There are no data from the use of satralizumab in pregnant women. Studies in monkeys do not indicate harmful effects with respect to reproductive toxicity (see section 5.3).

As a precautionary measure, it is preferable to avoid the use of Enspryng during pregnancy.

Breast-feeding

It is unknown whether satralizumab is excreted in human breast milk. Human IgG is known to be excreted in breast milk during the first days after birth, which is decreasing to low concentrations soon afterwards; consequently, a risk to breast-fed infants cannot be excluded during this short period. Afterwards, use of Enspryng could be considered during breast-feeding only if clinically needed.

Fertility

No clinical data are available on the effect of satralizumab on human fertility. Animal studies showed no impairment of male or female fertility (see section 5.3).

4.7. Effects on ability to drive and use machines

Enspryng has no or negligible influence on the ability to drive and use machines.

4.8. Undesirable effects

Summary of the safety profile

The most frequently reported adverse reactions observed were: headache (19.2%), arthralgia (13.5%), white blood cell count decreased (13.5%), hyperlipidaemia (13.5%), and injection-related reactions (12.5%).

Tabulated list of adverse reactions

Table 3 summarises the adverse reactions that have been reported in association with the use of satralizumab as a monotherapy or in combination with IST in clinical trials.

Adverse reactions from clinical trials (Table 3) are listed by MedDRA system organ class. Adverse reactions are presented using number of adverse events per 100 patient years and by frequency figures. The corresponding frequency category for each adverse reaction is based on frequency figures and the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000).

Table 3: Adverse reactions

System Organ Class

Frequency

Very common

Common

Blood and lymphatic system disorders

Hypofibrinogenaemia

Metabolism and nutrition disorders

Hyperlipidaemia

Psychiatric disorders

Insomnia

Nervous system disorders

Headache

Migraine

Cardiac disorders

Bradycardia

Vascular disorders

Hypertension

Respiratory, thoracic and mediastinal disorders

Allergic rhinitis

Gastrointestinal disorders

Gastritis

Skin and subcutaneous tissue disorders

Rash,

pruritus

Musculoskeletal and connective tissue disorders

Arthralgia

Musculoskeletal stiffness

General disorders and administration site conditions

Injection-related reactions

Peripheral oedema

Investigations

White blood cell count decreased

Neutrophil count decreased

platelet count decreased,

transaminases increased,

blood bilirubin increased, weight increased

Description of selected adverse reactions

Injection-related reactions (IRRs)

IRRs reported in patients treated with satralizumab were predominantly mild to moderate, and most occurred within 24 hours after injections. The most commonly reported systemic symptoms were diarrhoea and headache. The most commonly reported local injection site reactions were flushing, erythema, pruritus, rash and pain.

Body weight

In the double-blinded treatment period, body weight increase ≥15% from baseline were observed in 3.8% of patients treated with satralizumab (monotherapy or in combination with IST) as compared with 2.7% of patients receiving placebo (or plus IST).

Laboratory abnormalities

Neutrophils

In the double-blinded treatment period, decreased neutrophils were observed in 31.7% of patients treated with satralizumab (monotherapy or in combination with IST) as compared with 21.6% of patients receiving placebo (or placebo plus IST). The majority of neutrophil decreases were transient or intermittent.

9.6% of patients receiving satralizumab had neutrophils below 1 x 109/L, compared with 5.4% receiving placebo (or placebo plus IST).

Platelets

In the double-blinded treatment period, decreases in platelet count (below 150 × 109/l) occurred in 24.0% of patients on satralizumab (monotherapy or in combination with IST) as compared with 9.5% of patients receiving placebo or placebo plus IST. The decreased platelet count was not associated with bleeding events.

The majority of the decreased platelets were transient and not below 75 × 109/l.

Liver enzymes

In the double-blinded treatment period, elevations in ALT or AST occurred in 27.9% and 18.3% of patients treated with satralizumab (monotherapy or in combination with IST) respectively, compared with 12.2% and 13.5% of patients receiving placebo or placebo plus IST. The majority of the elevations were below 3 x ULN, were transient and resolved without interruption of satralizumab.

Elevations in ALT or AST >3 x ULN occurred in 2.9% and 1.9% of patients treated with satralizumab (monotherapy or in combination with IST) respectively. These elevations were not associated with increases in total bilirubin.

Elevations of ALT above 5 x ULN were observed 4 weeks after initiation of therapy in one (1%) patient receiving satralizumab in combination with IST; normalising after discontinuation of treatment, and satralizumab was not reintroduced in this patient (see sections 4.2 and 4.4).

Lipid parameters

In the double-blinded treatment period, 10.6% of patients receiving satralizumab (monotherapy or in combination with IST) experienced elevations in total cholesterol above 7.75 mmol/l as compared with 1.4% of patients receiving placebo (or placebo plus IST); 20.2% of patients receiving satralizumab experienced elevations in triglycerides above 3.42 mmol/l as compared with 10.8% of patients receiving placebo.

Paediatric population

The safety and efficacy of satralizumab have been studied in 9 children ≥12 years of age. Frequency, type and severity of adverse reactions in children from 12 years of age are expected to be the same as in adults.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

In the event of an overdose, the patient should be closely supervised, treated symptomatically, and supportive measures instituted as required.

🇷🇴 Known in Romania as

Medicines sold in Romania with the same active substance: Cunoscut în România ca

  • ENSPRYNG 120 mg prescriptionSATRALIZUMABUM · injection / infusion

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →

🇵🇱 Known in Poland as

Medicines sold in Poland with the same active substance: W Polsce znany jako

  • EnspryngSatralizumabum · injection / infusion

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →

💬 Ask about this leaflet

Ask anything about Enspryng 120 mg solution for injection in pre-filled syringe. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →